Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens

Harmer, Nicholas J; Chahwan, Richard

DOI: https://doi.org/10.1080/21505594.2016.1193278

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-168152
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution-NoDerivs 3.0 Unported (CC BY-ND 3.0) License.

Originally published at:
Harmer, Nicholas J; Chahwan, Richard (2016). Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens. Virulence, 7(6):623-626.
DOI: https://doi.org/10.1080/21505594.2016.1193278
Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens

Nicholas J. Harmer & Richard Chahwan

To cite this article: Nicholas J. Harmer & Richard Chahwan (2016) Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens, Virulence, 7:6, 623-626, DOI: 10.1080/21505594.2016.1193278

To link to this article: https://doi.org/10.1080/21505594.2016.1193278

© 2016 The Author(s). Published with license by Taylor & Francis Group, LLC. © Nicholas J. Harmer and Richard Chahwan

Published online: 24 Jun 2016.

Article views: 898

View related articles

View Crossmark data

Citing articles: 4 View citing articles
Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens

Nicholas J. Harmer and Richard Chahwan

Biosciences, University of Exeter, Exeter, Devon, UK

ARTICLE HISTORY Received 18 May 2016; Accepted 18 May 2016

KEYWORDS antibody multimerization; Burkholderia pseudomallei; IgG3; isotype switching; polysaccharide; vaccination

For many microbes, their polysaccharides (PS) are a critical part of their interaction with the mammalian immune system. Given their lower immunogenicity compared to protein peptides, PS can provide protection against both opsonization and phagocytosis, and in many cases actively protects bacteria against elements of both the innate and adaptive immune systems. Many bacterial species have traditionally been defined by their capsular polysaccharides (CPS) and polysaccharide O-antigens. These two PS are often highly variable between bacterial strains (e.g. ). The biosynthesis of both CPS and O-antigens generally results in long chains (often 10s to 100s of saccharide units) that consist of repeats of a short oligosaccharide. Although sugar moieties are poor substrates for eliciting an efficient adaptive immune response in vivo, PS based vaccines have delivered highly effective protection to humans against a range of microbial infections.

PS generally have to be administered conjugated to a carrier molecule (usually a protein) in order to engage T cells. Indeed, many of the effective licensed vaccines couple PS to bacterial toxins that generally provide a strong adjuvant effect. In the absence of a carrier, PS stimulate B cells independently by cross-linking antigen receptors. This produces an initial IgM mediated antibody response, which generally switches to an IgG response upon repeated boosting with antigen. The IgG response affords the greater part of the long term immunological memory to the antigen.

The mouse model is used for the large majority of initial vaccination studies. It has a very long track record of success, and the large volume of data available on the murine immune response makes it ideal for comparative studies. However, mice have known immunological differences compared to humans, and such discrepancies have the potential to confound some studies. Mice have different IgG subclasses that respond differently to certain cytokine treatments and different IgG receptors compared to human. Furthermore, mouse B cells tend to only switch antibody classes from IgM to IgG3 when stimulated with T-cell independent antigens. Humans, in contrast, tend to switch to the IgG2 subclass. Although the variable (antigen binding or Fv) regions of the antibodies remain identical, the different constant regions (or Fc) that the subclasses provide have a significant effect not only on antibody avidity but also on affinity. The former largely depends on the different capabilities of Fc regions to multimerise in vivo and in vitro; while the latter depends on the effect Fc regions have on Fv’s structural and conformational properties. Understanding the nature of this change in avidity and/or affinity is important for understanding the likely impacts that antibody class switching will have on transplanting vaccines between species. Furthermore, it is essential for the use of “humanized” antibodies for passive vaccination, in which there is increasing interest with the rise of multiple antimicrobial resistant bacteria.

In this issue of Virulence, Dillon et al. demonstrate that class switching has a profound impact on IgG3 antibodies against the CPS of the globally distributed emerging human pathogen Burkholderia pseudomallei. Interestingly, the CPS under investigation is an unusual polysaccharide, consisting of a linear homopolymer of a 2-O-acetyl-6-deoxy-heptopyranose. As the simplest form of polymer, the potential number of antigen sites is very dense. Indeed, a hexamer conjugated to protein is sufficient to confer protection in a mouse model. Dillon et al. demonstrate that an IgG3 anti-CPS antibody (3C5; composed of Vh6 and IgKV19/28 chains) raised against heat killed B. pseudomallei has a strong affinity for
purified CPS. However, when this antibody switches to other classes, the affinity significantly drops, by an order of magnitude. In contrast, an independent IgG1 class monoclonal (2A5; composed of Vh6 and IgKV21 chains) raised against a conjugate of purified CPS and albumin (T cell dependent antigen) showed very similar affinity when switched to other IgG classes. These effects are mirrored in the activity of the antibodies on ELISA in vitro; however, whether the monoclonal will behave similarly under physiological conditions in vivo remains to be seen.

These results from Dillon et al. strongly suggest that the mouse IgG3 constant region provides a significant increase in antibody affinity against repetitive PS epitopes. Similar results have been observed with PS from *Streptococcus pyogenes* and *Bacillus anthracis*. Taken together, these results suggest that the constant region of mouse IgG3 acts to polymerize antibodies together to increase the avidity effect. This multimerization has been postulated to be non-covalent in nature. However, it is known that human IgG2 (which like murine IgG3 usually responds to PS antigens) forms covalent dimers under some circumstances. It is therefore remotely possible that covalent bonding might also be involved in the multimerization of mouse IgG3.

The above rationale does not preclude the possibility that part of this effect is caused by structural changes in the variable region induced specifically by the IgG3 constant region in 3C5 monoclonals. Indeed, 2 previous studies by the Scharff and Casadevall labs have shown that F\textsubscript{ab} identical antibodies differing only in isotype class demonstrated differences in antigen specificity and affinity. Further studies investigating whether the F\textsubscript{c} region could impose conformational constraints on the F\textsubscript{ab} to alter its epitope binding structure suggested that F\textsubscript{c} regions could indeed do that in 2 independent experimental setups. Dillon et al. prepared F\textsubscript{ab} fragments of their 3C5 IgG3 antibody to address the possibility that the mouse IgG3 constant region causes specific secondary structure changes that affect affinity. These F\textsubscript{ab} fragments, as expected, showed a further drop in affinity in comparison to the isotype switched antibodies, reflecting the loss of the avidity and/or affinity effect. Dillon et al.’s result still cannot exclude the involvement of the IgG3 F\textsubscript{c} from affecting the conformational structure of the epitope binding region. However, the significant alteration in affinity suggests that the F\textsubscript{c} multimerization effect provides at least a large part of the affinity advantage of the IgG3 isotype in this case.

These results have significant implications for the use of mouse IgG3 derived antibodies for passive immunization. Because the same effect is not seen in human IgG3, IgG3 derived antibodies are likely to have a significant loss of affinity and/or avidity after being humanized. Furthermore, this effect raises questions for the validity of the mouse model for T cell independent antigens. As the IgG3 subclass is preferred for these antigens in the mouse, likely because of this constant domain linking effect, the same immunological response may not be seen in humans or other model species. Arguably, the F\textsubscript{c} class that behaves most like mouse IgG3 is human IgG2, and to a lesser extent human IgG1. Both human isotypes show a response to PS immunization, and both have been shown to covalently dimerize. Accordingly, it would be very interesting in the future to observe the binding effect of a humanized 3C5 using either human IgG2 or IgG1 F\textsubscript{c} regions. If both regions prove unsuccessful, it might be necessary to (chemically) modify human F\textsubscript{c} regions to mimic the biochemical properties of murine IgG3 before the monoclonals could be utilized for human passive immunization.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**References**

[1] Kanswal S, Katsenelson N, Allman W, Uslu K, Blake MS, Akkoyunlu M. Suppressive effect of bacterial polysaccharides on BAFF system is responsible for their poor immunogenicity. J Immunol 2011; 186:2430-43; PMID:21248261; http://dx.doi.org/10.4049/jimmunol.1002976

[2] Melin M, Jarva H, Siira L, Meri S, Kayhty H, Vakevainen M. *Streptococcus pneumoniae* capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun 2009; 77:676-84; PMID:19047408; http://dx.doi.org/10.1128/IAI.01186-08

[3] Shaw BM, Daubenspeck JM, Simmons WL, Dybvig K. EPS-I polysaccharide protects *Mycoplasma* from phagocytosis. FEMS Microbiol Lett 2013; 338:155-60; PMID:23190331; http://dx.doi.org/10.1111/1574-6968.12048

[4] Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D, Motherway MO, Shanahan F, Nally K, Doughan G, et al. Bifidobacterial surface-exopolsaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci U S A 2012; 109:2108-13; PMID:22308390; http://dx.doi.org/10.1073/pnas.1115621109

[5] Mishra M, Byrd MS, Sergeant S, Azad AK, Parsek MR, McPhail L, Schlesinger LS, Wozniak DJ. Pseudomonas aeruginosa PsI polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell Microbiol 2012; 14:95-106; PMID:21951860; http://dx.doi.org/10.1111/j.1462-5822.2011.01704.x
[6] Reckedel-Zenteno SL, DeVinney R, Woods DE. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun 2005; 73:1106-15; PMID:15664954; http://dx.doi.org/10.1128/IAI.73.2.1106-1115.2005

[7] Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins M, Donohoe K, Harris D, Murphy L, Quail MA, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006; 2:e31; PMID:16532061; http://dx.doi.org/10.1371/journal.pgen.0020031

[8] Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 2006; 75:39-68; PMID:16756484; http://dx.doi.org/10.1146/annurev.biochem.75.103004.142545

[9] Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 1998; 16:1391-5; PMID:9711777; http://dx.doi.org/10.1016/S0264-410X(98)00097-8

[10] Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko J, Quilici MA, Raju TS, Chin CN, Vafa O, Brezski RJ. Mestas J, Hughes CC. Of mice and not men: differences in isotype expression of immunoglobulins differing in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol 1994; 31:577-84; PMID:7515151; http://dx.doi.org/10.1016/S0168-1215(94)00048-8

[11] Davis MM. A prescription for human immunology. J Immunol 2004; 172:2731-8; PMID:14978070; http://dx.doi.org/10.4049/jimmunol.172.5.2731

[12] Avidity confers FcgammaR binding and immune effector function to aglycosylated immunoglobulin G1. J Mol Biol 2012; 25:147-54; PMID:22407978; http://dx.doi.org/10.1052/jmr.2015

[13] Cooper LJ, Robertson D, Granzow R, Greenspan NS. Variable domain-identical antibodies exhibit different paratopes. J Biol Chem 2012; 287:35409-17; PMID:22930758; http://dx.doi.org/10.1074/jbc.M112.404483

[14] Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol 2005; 174:2132-42; PMID:15699144; http://dx.doi.org/10.4049/jimmunol.174.4.2132

[15] Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayaar J, Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Cadoz M. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006; 2:e31; PMID:16532061; http://dx.doi.org/10.1371/journal.pgen.0020031

[16] Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 2006; 75:39-68; PMID:16756484; http://dx.doi.org/10.1146/annurev.biochem.75.103004.142545

[17] Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 1998; 16:1391-5; PMID:9711777; http://dx.doi.org/10.1016/S0264-410X(98)00097-8

[18] Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko J, Quilici MA, Raju TS, Chin CN, Vafa O, Brezski RJ. Mestas J, Hughes CC. Of mice and not men: differences in isotype expression of immunoglobulins differing in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol 1994; 31:577-84; PMID:7515151; http://dx.doi.org/10.1016/S0168-1215(94)00048-8

[19] Cooper LJ, Robertson D, Granzow R, Greenspan NS. Variable domain-identical antibodies exhibit different paratopes. J Biol Chem 2012; 287:35409-17; PMID:22930758; http://dx.doi.org/10.1074/jbc.M112.404483

[20] Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol 2005; 174:2132-42; PMID:15699144; http://dx.doi.org/10.4049/jimmunol.174.4.2132

[21] Janda A, Casadevall A. Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure. Mol Immunol 2010; 47:1421-5; PMID:20299100; http://dx.doi.org/10.1016/j.molimm.2010.02.018

[22] Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St Michael F, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun 2013; 81:915-22; PMID:23297385; http://dx.doi.org/10.1128/IAI.01184-12

[23] Dillon MJ, Loban RA, Reed DE, Thorkildsson P, Pughheo K, Pandit SG, Brett PJ, Burtnick MN, AuCoin DP. Contribution of Murine IgG Fc Regions to Antibody Binding to the Capsule of Burkholderia pseudomallei. Virulence 2016; 691-701; http://dx.doi.org/10.1080/21505594.2016.1176655

[24] Currie BJ, Kaestli E. Epidemiology: A global picture of melioidosis. Nature 2016; 529:290-1; PMID:26791716; http://dx.doi.org/10.1038/529290a

[25] Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Mozes CL, Rolim DB, Bertherat E, Day NP, Peacock SJ, et al. Predicted global distribution of and burden of melioidosis. Nat Microbiol 2016; 1:15008; PMID:26877885; http://dx.doi.org/10.1038/nmicrobiol.2015.8

[26] Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med 2012; 367:1035-44; PMID:22970946; http://dx.doi.org/10.1056/NEJMra1204699

[27] Cuccui J, Milne TS, Harmer N, George AJ, Harding SV, Dean RE, Scott AE, Sarkar-Tyson M, Wren BW, Titball RW, et al. Characterization of the Burkholderia pseudomallei K96243 capsular polysaccharide I coding region. Infect Immun 2012; 80:1209-21; PMID:22252864; http://dx.doi.org/10.1128/IAI.05805-11

[28] Scott AE, Christ WJ, Stokes MG, Lohman GJ, Guo Y, Jones M, Titball RW, Atkins TP, Campbell AS, et al. Protection against experimental melioidosis with a synthetic manno-heptopyranose hexasaccharide glycoconjugate. Bioconjug Chem 2016; http://dx.doi.org/10.1021/acs.bioconjchem.5b00525

[29] Cooper LJ, Robertson D, Granzow R, Greenspan NS. Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol 1994; 31:577-84; PMID:7515151; http://dx.doi.org/10.1016/0161-5890(94)00165-1

[30] Hovenden M, Hubbard MA, Aucoin DP, Thorkildson P, Reed DE, Welch WH, Lyons CR, Lovchik JA, Kozel TR.
IgG subclass and heavy chain domains contribute to binding and protection by mAbs to the poly gamma-D-glutamic acid capsular antigen of Bacillus anthracis. PLoS Pathog 2013; 9:e1003306; PMID:23637599; http://dx.doi.org/10.1371/journal.ppat.1003306

[31] Cooper LJ, Schimenti JC, Glass DD, Greenspan NS. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J Immunol 1991; 146:2659-63; PMID:1901882

[32] Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol 2003; 170:3134-8; PMID:12626570; http://dx.doi.org/10.4049/jimmunol.170.6.3134

[33] Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5:520; PMID:25368619; http://dx.doi.org/10.3389/fimmu.2014.00520

[34] Yang J, Goetze AM, Flynn GC. Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2. Mol Immunol 2014; 58:108-15; PMID:24321397; http://dx.doi.org/10.1016/j.molimm.2013.11.011